AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.

Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025, ...

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in comb ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

Health Canada has granted a Notice of Compliance (NOC) for Imfinzi® (durvalumab) for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with ...

Health Canada has granted a Notice of Compliance (NOC) for Imfinzi® (durvalumab) for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and ...

Health Canada has granted a Notice of Compliance (NOC) for Imfinzi ® (durvalumab) for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine ...

AstraZeneca’s Imfinzi (durvalumab) has been granted priority review by the US Food and Drug Administration (FDA) to treat early-stage gastric cancer. The decision specifically applies to patients with ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI ® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable ...